Danaher Announces Pricing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering

Danaher Announces Pricing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering WASHINGTON, May 8, 2020 /PRNewswire/ — Danaher Corporation (NYSE:DHR) (“Danaher”) announced today that it has priced concurrent offerings of 9,509,203 shares of common stock at a price to the public of $163.00 per share and 1,550,000 shares of 5.00% Series B Mandatory Convertible Preferred... Read more

Danaher Announces Offerings Of Common Stock And Mandatory Convertible Preferred Stock

Danaher Announces Offerings Of Common Stock And Mandatory Convertible Preferred Stock WASHINGTON, May 7, 2020 /PRNewswire/ — Danaher Corporation (NYSE:DHR) (“Danaher”) announced today that it has commenced concurrent offerings of $1.25 billion of shares of common stock and $1.25 billion of shares of Series B Mandatory Convertible Preferred Stock, subject to market and other conditions (the offerings).... Read more

Danaher Reports First Quarter 2020 Results

WASHINGTON, May 6, 2020 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the quarter ended April 3, 2020.  All results in this release reflect only continuing operations unless otherwise noted. For the first quarter 2020, net earnings were $595.1 million, or $0.81 per diluted common share.  Non-GAAP adjusted diluted net earnings... Read more

Danaher Completes Sale Of Certain Businesses To Sartorius AG To Satisfy Regulatory Requirement For Cytiva Acquisition

Danaher Completes Sale Of Certain Businesses To Sartorius AG To Satisfy Regulatory Requirement For Cytiva Acquisition WASHINGTON, April 30, 2020 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher”) announced today it completed the sale of its label-free biomolecular characterization, chromatography hardware and resins, microcarriers and particle validation standards, single use tangential flow filtration systems, and stainless steel... Read more

Danaher Provides Update On First Quarter 2020 Financial Performance And Schedules First Quarter Earnings Conference Call

Danaher Provides Update On First Quarter 2020 Financial Performance And Schedules First Quarter Earnings Conference Call WASHINGTON, April 13, 2020 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher” or “the Company”) announced today that for the quarter ended April 3, 2020 it expects revenue growth of approximately 3.0% and non-GAAP core revenue growth of approximately 4.5%.... Read more

Danaher Completes Acquisition Of The Biopharma Business Of General Electric Life Sciences; Business Will Be Called Cytiva

Danaher Completes Acquisition Of The Biopharma Business Of General Electric Life Sciences; Business Will Be Called Cytiva WASHINGTON, March 31, 2020 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher”) announced today the completion of its acquisition of the Biopharma business from General Electric Company’s (NYSE: GE) Life Sciences division. As part of Danaher, the business will... Read more

Danaher Receives Clearance From U.S. Federal Trade Commission For The Acquisition Of The Biopharma Business Of General Electric Life Sciences

Danaher Receives Clearance From U.S. Federal Trade Commission For The Acquisition Of The Biopharma Business Of General Electric Life Sciences WASHINGTON, March 19, 2020 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher”) announced today that the U.S. Federal Trade Commission (the “FTC”) has accepted the proposed consent order in connection with Danaher’s definitive agreement with General... Read more